Literature DB >> 3348057

Cervicovaginal and endometrial cytology in ovarian cancer.

T Takashina1, M Ono, Y Kanda, S Sagae, O Hayakawa, E Ito.   

Abstract

The clinical significance of cytologic examination was studied in 114 patients with ovarian cancer who had received preoperative cytologic examinations. The overall positive rate of the cytologic examinations was 26.3% (30 of 114): 22 (19.3%) of the 114 cases had positive cervicovaginal smears while 13 of 31 endometrial aspiration smears (41.9%) were positive. The positive rate was not related to the volume of ascites but rather to its presence or absence. Thus, if ascites was observed, the positive rate was about 2.1 times higher than if it was absent. In two of four cases of ovarian cancer with no endometrial invasion but a positive cytologic examination of ascitic fluid, fallopian tube specimens contained cancer cells; this suggests that ovarian cancer cells may reach the cervix and/or vagina by passing through the fallopian tube, particularly if ascites is present. Since cytologic examination, especially of endometrial aspiration smears, shows a high positive rate if ovarian cancer cells are observed in the abdominal cavity, cytology should be used as an important ancillary method for the assessment of ovarian cancer.

Entities:  

Mesh:

Year:  1988        PMID: 3348057

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  3 in total

1.  Cytologic findings of cervicovaginal smears in women with uterine papillary serous carcinoma.

Authors:  Ji-Young Park; Hye Sun Kim; Sung Ran Hong; Yi Kyeong Chun
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

2.  Repurposing the Pap smear: one step closer to gynecologic cancer screening.

Authors:  Shannon N Westin; Gordon B Mills; Andrea P Myers
Journal:  Sci Transl Med       Date:  2013-01-09       Impact factor: 17.956

3.  Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity.

Authors:  I Otsuka; S Kameda; K Hoshi
Journal:  Br J Cancer       Date:  2013-07-18       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.